TY - CHAP PY - 2013 DA - 2013// TI - Health at a Glance 2013 BT - OECD Indicators ID - ref1 ER - TY - CHAP PY - 2013 DA - 2013// BT - Annual report 2012 PB - PMPRB CY - Ottawa ID - ref2 ER - TY - CHAP PY - 2013 DA - 2013// BT - National health expenditure trends, 1975 to 2012 PB - CIHI CY - Ottawa ID - ref3 ER - TY - CHAP PY - 2012 DA - 2012// BT - Drug expenditure in Canada, 1985 to 2011 PB - CIHI CY - Ottawa ID - ref4 ER - TY - CHAP PY - 2012 DA - 2012// BT - Drivers of prescription drug spending in Canada PB - CIHI CY - Ottawa ID - ref5 ER - TY - JOUR PY - 2012 DA - 2012// TI - New drugs and indications in 2011: France is better focused on patients’ interests after the Mediator scandal, but stagnation elsewhere JO - Prescrire Int VL - 21 ID - ref6 ER - TY - CHAP PY - 2013 DA - 2013// BT - Drug expenditure in Canada, 1985 to 2012 PB - CIHI CY - Ottawa ID - ref7 ER - TY - STD TI - 2009/10 report card for the Ontario Drug Benefit Program.http://www.health.gov.on.ca/en/public/programs/drugs/publications/opdp/docs/odb_report_09.pdf, Ontario Ministry of Health and Long-Term Care UR - http://www.health.gov.on.ca/en/public/programs/drugs/publications/opdp/docs/odb_report_09.pdf ID - ref8 ER - TY - STD TI - 2010/11 report card for the Ontario Drug Benefit Program.http://www.health.gov.on.ca/en/public/programs/drugs/publications/opdp/docs/odb_report_10.pdf, Ontario Ministry of Health and Long-Term Care UR - http://www.health.gov.on.ca/en/public/programs/drugs/publications/opdp/docs/odb_report_10.pdf ID - ref9 ER - TY - BOOK PY - 2013 DA - 2013// TI - CLHIA report on prescription drug policy: ensuring the accessibility, affordability and sustainability of prescription drugs in Canada PB - CLHIA CY - Toronto ID - ref10 ER - TY - JOUR AU - Grootendorst, P. AU - Hollis, A. PY - 2011 DA - 2011// TI - The Canada-European Union Comprehensive Economic & Trade Agreement: an economic impact assessment of proposed pharmaceutical intellectual property provisions JO - J Generic Med VL - 8 UR - https://doi.org/10.1177/1741134311408275 DO - 10.1177/1741134311408275 ID - Grootendorst2011 ER - TY - BOOK PY - 2011 DA - 2011// TI - Reality check: analysis of the CGPA’s economic assessment of proposed pharmaceutical IP provisions PB - D CY - Ottawa ID - ref12 ER - TY - BOOK AU - Kierans, P. AU - Wall, K. AU - Daley, J. PY - 2011 DA - 2011// TI - CETA trade negotiations 2011 - drug market exclusivity in the EU and Canada PB - Norton Rose CY - Toronto ID - Kierans2011 ER - TY - BOOK AU - Hollis, A. AU - Grootendorst, P. PY - 2012 DA - 2012// TI - Drug market exclusivity in the EU and Canada: problems with Norton Rose’s comptive analysis ID - Hollis2012 ER - TY - JOUR AU - Downing, N. AU - Aminawung, J. AU - Shah, N. AU - Braunstein, J. AU - Krumholz, H. AU - Ross, J. PY - 2012 DA - 2012// TI - Regulatory review of novel therapeutics - comparison of three regulatory agencies JO - N Engl J Med VL - 366 UR - https://doi.org/10.1056/NEJMsa1200223 DO - 10.1056/NEJMsa1200223 ID - Downing2012 ER - TY - BOOK AU - Correa, C. PY - 2002 DA - 2002// TI - Protection of data submitted for the registration of pharmaceuticals: implementing the standards of the TRIPS agreement PB - The South Centre CY - Geneva ID - Correa2002 ER - TY - JOUR PY - 2006 DA - 2006// TI - Regulations amending the Food and Drug Regulations (Data Protection) JO - Can Gazette Part II VL - 140 ID - ref17 ER - TY - BOOK PY - 2013 DA - 2013// TI - Technical summary of final negotiated outcomes: Canada-European Union comprehensive economic and trade deal PB - Government of Canada CY - Canada ID - ref18 ER - TY - JOUR AU - Faunce, T. AU - Lexchin, J. PY - 2007 DA - 2007// TI - Linkage pharmaceutical evergreening in Canada and Australia JO - Aust N Z Health Policy VL - 4 UR - https://doi.org/10.1186/1743-8462-4-8 DO - 10.1186/1743-8462-4-8 ID - Faunce2007 ER - TY - BOOK PY - 2013 DA - 2013// TI - Special 301 submission 2013 PB - PhRMA CY - Washington D.C ID - ref20 ER - TY - BOOK AU - Bartucci, S. AU - Dawson, L. PY - 2013 DA - 2013// TI - Pills patents & profits III PB - MacDonald-Laurier Institute CY - Ottawa ID - Bartucci2013 ER - TY - BOOK AU - Bouchard, R. PY - 2011 DA - 2011// TI - Patently innovative: how pharmaceutical firms use emerging patent law to extend monopolies on blockbuster drugs PB - Biohealthcare Publishing Ltd CY - Cambridge ID - Bouchard2011 ER - TY - BOOK PY - 2011 DA - 2011// TI - Commission calls on Italy to comply with EU rules on marketing authorisation of generic drugs PB - European Commission CY - Brussels ID - ref23 ER - TY - BOOK PY - 2012 DA - 2012// TI - Canada-EU drug patent demand in trade talks costs almost $2B PB - CBC News CY - Canada ID - ref24 ER - TY - BOOK PY - 2013 DA - 2013// TI - Ottawa urged to release papers on drug costs after CETA PB - CBC News CY - Canada ID - ref25 ER - TY - BOOK PY - 2012 DA - 2012// TI - CETA IP changes - impact timeline PB - D CY - Ottawa ID - ref26 ER - TY - STD TI - Canada yields on some EU drug IPR demands, but fends off others. 2013, Inside US Trade ID - ref27 ER - TY - BOOK PY - 2000 DA - 2000// TI - Canadians’ access to insurance for prescription medicines: volume 2: the uninsured and the under-insured ID - ref28 ER - TY - JOUR AU - Law, M. AU - Cheng, L. AU - Dhalla, I. AU - Heard, D. AU - Morgan, S. PY - 2012 DA - 2012// TI - The effect of cost on adherence to prescription medications in Canada JO - CMAJ VL - 184 UR - https://doi.org/10.1503/cmaj.111270 DO - 10.1503/cmaj.111270 ID - Law2012 ER -